News
1d
Zacks Investment Research on MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...
Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks. Compass Pathways ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
8d
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results